


Stabilis



Dobutamine hydrochloride



Noms commerciaux

Cardiforce	Inde
Cardiject	Inde, Iran, Maroc
Dobcar	Turquie
Dobine	Chili
Dobucard	Argentine
Dobucin	Equateur
Dobucor	Espagne
Dobuject	Arabie Saoudite, Colombie, Egypte, Finlande, Mexique, Pologne, Tunisie
Doburan	Vénézuéla
Dobutabag	Turquie
Dobutamex	Iran
Dobutamin	Allemagne, Autriche, Hongrie, Irlande, Norvège, Pologne
Dobutamina	Argentine, Chili, Colombie, Equateur, Espagne, Italie, Mexique, Pérou, Portugal
Dobutamine	Belgique, Canada, Egypte, Etats Unis d'Amérique, Grande Bretagne, Irlande, Malaisie, Maroc, Pologne, Tunisie
Dobutrex	Arabie Saoudite, Belgique, Colombie, Danemark, Espagne, Grande Bretagne, Irlande, Italie, Luxembourg, Mexique, Norvège, Pays bas, Suède, Suisse
Duwig	Argentine
Endobil	Chili
Inotop	Autriche
Inotrex	Grèce, Portugal
Insucard	Brésil
Miozac	Italie
Oxiken	Mexique
Posiject	Grande Bretagne



Stabilité des solutions

Icon 1	Icon 2	Icon 3	Icon 4	Icon 5	Icon 6	Icon 7	Icon 8	Icon 9
		0,25 mg/ml	5°C		7			1045
		1 mg/ml	25°C		48			1058

PVC		0,25 mg/ml	5°C		7			1045
PVC		1 mg/ml	25°C		48			628
PVC		10 mg/ml	25°C		12			4141
PVC		10 mg/ml	35°C		12			4141
PVC		10 mg/ml	4°C		7			4141
PVC		1 & 5 mg/ml	5°C		30			197
PVC	RL	1 mg/ml	25°C		48			628
PVC		1 mg/ml	25°C		48			628
PVC		1 mg/ml	25°C		48			1058
PVC		0,0025 mg/ml	26°C		4			2371
PVC		0,0025 mg/ml	4°C		24			2371
PVC		0,005 mg/ml	26°C		24			2371
PVC		0,005 mg/ml	37°C		24			2371
PVC		0,005 mg/ml	4°C		24			2371
PVC		0,0075 mg/ml	26°C		24			2371
PVC		0,0075 mg/ml	37°C		24			2371
PVC		0,0075 mg/ml	4°C		24			2371
PE		0,5 mg/ml	22°C		24			1067
PE		0,5 mg/ml	4°C		24			1067
PE		10 mg/ml	2-8°C		365			4584
PE		10 mg/ml	-25 >> -15°C		90			4584
PE		10 mg/ml	23-27°C		30			4584
PE		10 mg/ml	-25 >> -15°C		21			4584
PE		10 mg/ml	20°C		35			3293
PE		10 mg/ml	4°C		42			3293
PE		5 mg/ml	23-25°C		48			206
PE		5 mg/ml	25°C		24			196
PE		5 mg/ml	4°C		48			206
AT-Closed Visi*		10 mg/ml	-25 >> -15°C		365			4584
AT-Closed Visi*		10 mg/ml	2-8°C		365			4584
AT-Closed Visi*		10 mg/ml	23-27°C		365			4584
?		4 mg/ml	23°C		30			1753
?		4 mg/ml	5°C		30			1753



Stabilité en mélange

		0,25 & 5 mg/ml	20°C-25°C		Tirofiban : 50 µg/ml	4		1603
		0,25 mg/ml	5°C		Verapamil hydrochloride : 0,16 mg/ml	7		1045
		2 mg/ml	?		Nitroprusside sodium : 0,2 mg/ml Nitroglycerin : 0,2 mg/ml	24		1109
		2,5 mg/ml	20°C-25°C		Labetalol hydrochloride : 1 mg/ml	4		199
		5 mg/ml	22°C		Nitroprusside sodium : 1,2 mg/ml	24		3381
		5 mg/ml	22°C		Norepinephrine bitartrate : 0,06 mg/ml	24		3381
		5 mg/ml	22°C		Norepinephrine bitartrate : 0,06 mg/ml Amiodarone hydrochloride : 12,5 mg/ml	24		3381
		4 mg/ml	22°C-23°C		Milrinone lactate : 0,2 mg/ml	4		813
		1 mg/ml	23°C		Zidovudine : 2 mg/ml	24		1878
		1 mg/ml	4°C		Zidovudine : 2 mg/ml	24		1878
		0,25 mg/ml	5°C		Verapamil hydrochloride : 0,16 mg/ml	7		1045
		0,25 & 1 mg/ml	?		Ranitidine hydrochloride : 0,05 & 2 mg/ml	48		210
		2 mg/ml	23°C		Flumazenil : 0,02 mg/ml	24		187
		5 mg/ml	22°C		Nitroprusside sodium : 1,2 mg/ml	24		3381
		5 mg/ml	22°C		Norepinephrine bitartrate : 0,06 mg/ml	24		3381
		5 mg/ml	22°C		Norepinephrine bitartrate : 0,06 mg/ml Amiodarone hydrochloride : 12,5 mg/ml	24		3381
		8 mg/ml	22-25°C		Dopamine hydrochloride : 8 mg/ml	24		1506
		8 mg/ml	22-25°C		Methadone hydrochloride : 0.2 mg/ml	24		1506
		8 mg/ml	22-25°C		Midazolam hydrochloride : 4 mg/ml	24		1506



























































Facteur influençant la stabilité

				3293
				197
				1041
				1058
				3606
	PH >7			3606
	PH > 6			197



Compatibilités

			
			336
			3595
			4651
			4491
			3201
			92
			240
			3
			1041
			1058
			4119
			3823
			1041
			1036
			4119
			4119
			3824
			921
			1982
			1964
			402
			1041
			1221
			99



















































		Dobutamine hydrochloride : 4 mg/ml Bivalirudin : 5 mg/ml		1713
		Dobutamine hydrochloride : 12,5 mg/ml Bivalirudin : 5 mg/ml		1944
		Dobutamine hydrochloride : 4 mg/ml Bivalirudin		3539
		Dobutamine hydrochloride : 12.5 mg/ml Bivalirudin		3539
		Dobutamine hydrochloride : 1 mg/ml Bretylum tosilate : 2 mg/ml		1058
		Dobutamine hydrochloride : 2 mg/ml Bretylum tosilate : 8 & 50 mg/ml		1041
		Dobutamine hydrochloride : 2 mg/ml Bumetanide : 0.25 mg/ml		1041
		Dobutamine hydrochloride : 12.5 mg/ml Caffeine : 10 mg/ml		3964
		Dobutamine hydrochloride : 1 mg/ml Calcium chloride : 2 mg/ml		1058
		Dobutamine hydrochloride : 0,18 mg/ml Calcium chloride : 9,1 mg/ml		1221
		Dobutamine hydrochloride : 2 mg/ml Calcium chloride : 100 mg/ml		1041
		Dobutamine hydrochloride Calcium gluconate		3644
		Dobutamine hydrochloride : 2 mg/ml Calcium gluconate : 100 mg/ml		1041
		Dobutamine hydrochloride : 1 mg/ml Calcium gluconate : 2 mg/ml		1058
		Dobutamine hydrochloride : 4 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Dobutamine hydrochloride : 1 mg/ml Caspofungin acetate : 0.5 mg/ml		2233
		Dobutamine hydrochloride : 1 mg/ml Cefepime dihydrochloride : 125 mg/ml		2141
		Dobutamine hydrochloride : 4 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Dobutamine hydrochloride : 4.2 mg/ml Cefmetazole sodium : 100 mg/ml		93
		Dobutamine hydrochloride : 4 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Dobutamine hydrochloride : 4 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Dobutamine hydrochloride : 4 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Dobutamine hydrochloride : 1 mg/ml Ceftazidime : 125 mg/ml		2141
		Dobutamine hydrochloride Ceftobiprole medocaril sodium		4650
		Dobutamine hydrochloride : 4 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Dobutamine hydrochloride : 4 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269

		Dobutamine hydrochloride : 4 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Dobutamine hydrochloride : 4 mg/ml		301
		Dobutamine hydrochloride : 2 mg/ml Ciprofloxacin lactate : 2 mg/ml		285
		Dobutamine hydrochloride : 0.25 mg/ml Ciprofloxacin lactate : 2 mg/ml		288
		Dobutamine hydrochloride : 4 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
		Dobutamine hydrochloride : 4 mg/ml Cladribine : 0.5 mg/ml		1496
		Dobutamine hydrochloride : 4 mg/ml Cladribine : 0.015 mg/ml		1496
		Dobutamine hydrochloride : 2 mg/ml Clonidine hydrochloride : 0,018 mg/ml		2018
		Dobutamine hydrochloride : 8 mg/ml Clonidine hydrochloride : 0.0075 mg/ml		1506
		Dobutamine hydrochloride : 12,5 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Dobutamine hydrochloride Conivaptan		3715
		Dobutamine hydrochloride : 4 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Dobutamine hydrochloride : 2 mg/ml Diazepam : 5 mg/ml		1041
		Dobutamine hydrochloride : 1 mg/ml Digoxin : 4 µg/ml		1058
		Dobutamine hydrochloride : 2 mg/ml Diltiazem hydrochloride : 1 mg/ml		524
		Dobutamine hydrochloride : 4 mg/ml Diltiazem hydrochloride : 1 mg/ml		314
		Dobutamine hydrochloride : 1 mg/ml Diltiazem hydrochloride : 1 & 5 mg/ml		198
		Dobutamine hydrochloride Dimenhydrinate		2087
		Dobutamine hydrochloride : 4 mg/ml Docetaxel : 0.9 mg/ml		1754
		Dobutamine hydrochloride : 0,17 mg/ml Dopamine hydrochloride : 5,52 mg/ml		1221
		Dobutamine hydrochloride : 8 mg/ml Dopamine hydrochloride : 8 mg/ml		1506
		Dobutamine hydrochloride : 2 mg/ml Dopamine hydrochloride : 1.6 mg/ml		1041
		Dobutamine hydrochloride : 4 mg/ml Dopamine hydrochloride : 3.2 mg/ml		314
		Dobutamine hydrochloride : 1 mg/ml Dopamine hydrochloride : 1.6 mg/ml		1058
		Dobutamine hydrochloride : 10 mg/ml Dopamine hydrochloride : 20 mg/ml		3823
		Dobutamine hydrochloride : 1 mg/ml		1058
		Dobutamine hydrochloride : 4 mg/ml Doripenem : 5 mg/ml		2262

		Dobutamine hydrochloride		3606
		Dobutamine hydrochloride : 4 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Dobutamine hydrochloride : 0,91 mg/ml Enalaprilate : 0,011 mg/ml		963
		Dobutamine hydrochloride : 1 mg/ml Enalaprilate : 0.05 mg/ml		1315
		Dobutamine hydrochloride : 1 mg/ml Enalaprilate : 0.0125 mg/ml		1703
		Dobutamine hydrochloride : 4 mg/ml Epinephrine hydrochloride : 20 µg/ml		314
		Dobutamine hydrochloride : 2 mg/ml Epinephrine hydrochloride : 0.1 µg/ml		1041
		Dobutamine hydrochloride Eptifibatide		3934
		Dobutamine hydrochloride : 4,1 mg/ml Eravacycline : 0,6 mg/ml		4434
		Dobutamine hydrochloride : 8 mg/ml Esomeprazole sodium : 0.32 mg/ml		1506
		Dobutamine hydrochloride : 4 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Dobutamine hydrochloride : 1 mg/ml Famotidine : 0.2 mg/ml		398
		Dobutamine hydrochloride : 40 mg/ml Famotidine : 2 mg/ml		215
		Dobutamine hydrochloride : 4 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Dobutamine hydrochloride : 4 mg/ml Fentanyl citrate : 50 µg/ml		314
		Dobutamine hydrochloride : 2 mg/ml		1041
		Dobutamine hydrochloride : 2 mg/ml Fentanyl citrate : 50 µg/ml		63
		Dobutamine hydrochloride : 8 mg/ml Fentanyl citrate : 30 µg/ml		1506
		Dobutamine hydrochloride : 0.5 mg/ml Flucloxacillin sodium : 20 mg/ml		1232
		Dobutamine hydrochloride : 2 mg/ml Fluconazole : 2 mg/ml		255
		Dobutamine hydrochloride : 2 mg/ml Flumazenil : 0,02 mg/ml		187
		Dobutamine hydrochloride : 12.5 mg/ml Foscarnet sodium : 24 mg/ml		73
		Dobutamine hydrochloride : 4.1 mg/ml Fosfomycin : 30 mg/ml		4055
		Dobutamine hydrochloride : 2 mg/ml Furosemide : 10 mg/ml		1041
		Dobutamine hydrochloride : 4 mg/ml Furosemide : 10 mg/ml		314
		Dobutamine hydrochloride : 50 mg/ml		939
		Dobutamine hydrochloride : 1 mg/ml Furosemide : 1 mg/ml		1058















		Dobutamine hydrochloride : 8 mg/ml Furosemide : 2 mg/ml		1506
		Dobutamine hydrochloride : 5 mg/ml Furosemide : 10 mg/ml		3210
		Dobutamine hydrochloride : 12,5 mg/ml	RL	4603
		Dobutamine hydrochloride : 0.5 mg/ml Furosemide : 1 mg/ml		1232
		Dobutamine hydrochloride : 8 mg/ml Furosemide : 2 mg/ml		1506
		Dobutamine hydrochloride : 4 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Dobutamine hydrochloride : 4 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Dobutamine hydrochloride : 4 mg/ml Haloperidol lactate : 0.5 & 5 mg/ml		403
		Dobutamine hydrochloride Heparin sodium		3540
		Dobutamine hydrochloride : 2 mg/ml Heparin sodium : 100 UI/ml		1352
		Dobutamine hydrochloride : 4 mg/ml Heparin sodium : 100 UI/ml		314
		Dobutamine hydrochloride : 2 mg/ml Heparin sodium : 100 UI/ml		1041
		Dobutamine hydrochloride : 4 mg/ml Heparin sodium : 100 UI/ml		295
		Dobutamine hydrochloride : 1 mg/ml Heparin sodium : 40 UI/ml		1058
		Dobutamine hydrochloride : 1 mg/ml Heparin sodium : 50 UI/ml		317
		Dobutamine hydrochloride : 2 mg/ml Heparin sodium : 10000 UI/ml		1041
		Dobutamine hydrochloride : 4 mg/ml Hetastarch : 60 mg/ml		1721
		Dobutamine hydrochloride : 0,2 mg/ml Hydralazine hydrochloride : 0,2 mg/ml		1221
		Dobutamine hydrochloride : 4 mg/ml Hydromorphone hydrochloride : 1 mg/ml		314
		Dobutamine hydrochloride Hydroxocobalamin		3932
		Dobutamine hydrochloride : 1 mg/ml Ibuprofen lysinate : 10 mg/ml		4419
		Dobutamine hydrochloride : 4 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
		Dobutamine hydrochloride : 1.2 mg/ml Indomethacin sodium trihydrate : 1 mg/ml		467
		Dobutamine hydrochloride : 2 mg/ml Insulin : 100 UI/ml		1041
		Dobutamine hydrochloride : 1 mg/ml Insulin : 1 UI/ml		1058
		Dobutamine hydrochloride : 5 mg/ml		316
		Dobutamine hydrochloride : 8 mg/ml Insulin : 1 UI/ml		1506

		Dobutamine hydrochloride : 5 mg/ml Insulin aspart : 1 UI/ml		1508
		Dobutamine hydrochloride : 4.1 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Dobutamine hydrochloride : 2 mg/ml Isoprenaline hydrochloride : 0.004 mg/ml		1041
		Dobutamine hydrochloride : 12.5 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
		Dobutamine hydrochloride : 4 mg/ml		1415
		Dobutamine hydrochloride : 2.5 mg/ml Labetalol hydrochloride : 1 mg/ml		199
		Dobutamine hydrochloride : 4 mg/ml Labetalol hydrochloride : 5 mg/ml		295
		Dobutamine hydrochloride : 4 mg/ml Labetalol hydrochloride : 2 mg/ml		314
		Dobutamine hydrochloride : 4 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Dobutamine hydrochloride : 2 mg/ml Levetiracetam : 100 mg/ml		4108
		Dobutamine hydrochloride : 12,5 mg/ml Levofloxacin : 5 mg/ml		1072
		Dobutamine hydrochloride : 1 mg/ml Lidocaine hydrochloride : 4 mg/ml		1058
		Dobutamine hydrochloride : 2 mg/ml Lidocaine hydrochloride : 8 mg/ml		1041
		Dobutamine hydrochloride : 4 mg/ml Linezolid : 2 mg/ml		1925
		Dobutamine hydrochloride : 4 mg/ml Lorazepam : 0.5 mg/ml		314
		Dobutamine hydrochloride : 0,17 mg/ml Magnesium sulfate : 83,3 mg/ml		1221
		Dobutamine hydrochloride : 1 mg/ml Magnesium sulfate : 2 mg/ml		1058
		Dobutamine hydrochloride : 1 mg/ml Meropenem : 1 & 20 mg/ml		266
		Dobutamine hydrochloride : 12.5 mg/ml Meropenem : 50 mg/ml		4319
		Dobutamine hydrochloride : 2 mg/ml Metaraminol : 0.2 mg/ml		1041
		Dobutamine hydrochloride : 8 mg/ml Methadone hydrochloride : 0.2 mg/ml		1506
		Dobutamine hydrochloride : 4 mg/ml Micafungin : 1.5 mg/ml		2108
		Dobutamine hydrochloride : 4 mg/ml Midazolam hydrochloride : 2 mg/ml		314
		Dobutamine hydrochloride : 4 mg/ml Midazolam hydrochloride : 1 mg/ml		295
		Dobutamine hydrochloride : 2 mg/ml Midazolam hydrochloride : 1 mg/ml		176
		Dobutamine hydrochloride : 8 mg/ml Midazolam hydrochloride : 4 mg/ml		1506

		Dobutamine hydrochloride : 8 mg/ml Midazolam hydrochloride : 4 mg/ml		1506
		Dobutamine hydrochloride : 4 mg/ml Milrinone lactate : 0.2 mg/ml		314
		Dobutamine hydrochloride : 16 mg/ml Milrinone lactate : 0.8 mg/ml		813
		Dobutamine hydrochloride : 8 mg/ml Morphine hydrochloride : 1 mg/ml		1506
		Dobutamine hydrochloride : 4 mg/ml Morphine sulfate : 2 mg/ml		314
		Dobutamine hydrochloride : 2 mg/ml Morphine sulfate : 10 mg/ml		1041
		Dobutamine hydrochloride : 12.5 mg/ml N-acetylcysteine : 200 mg/ml		3766
		Dobutamine hydrochloride : 12.5 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
		Dobutamine hydrochloride : 4 mg/ml Nicardipine hydrochloride : 1 mg/ml		314
		Dobutamine hydrochloride : 1 mg/ml Nicardipine hydrochloride : 0.1 mg/ml		1490
		Dobutamine hydrochloride : 4 mg/ml Nitroglycerin : 0.4 mg/ml		314
		Dobutamine hydrochloride : 2 mg/ml Nitroglycerin : 0.24 mg/ml		1041
		Dobutamine hydrochloride : 5 mg/ml Nitroprusside sodium : 1.2 mg/ml		2879
		Dobutamine hydrochloride : 5 mg/ml Nitroprusside sodium : 1,2 mg/ml		3177
		Dobutamine hydrochloride : 2 mg/ml Norepinephrine bitartrate : 0.064 mg/ml		1041
		Dobutamine hydrochloride : 5 mg/ml Norepinephrine bitartrate : 0.06 mg/ml		3381
		Dobutamine hydrochloride : 5 mg/ml Norepinephrine bitartrate : 0,06 mg/ml		3177
		Dobutamine hydrochloride : 4 mg/ml Norepinephrine bitartrate : 0.128 mg/ml		314
		Dobutamine hydrochloride : 10 mg/ml Norepinephrine bitartrate : 0.96 mg/ml		3823
		Dobutamine hydrochloride : 5 mg/ml Norepinephrine bitartrate : 0.06 mg/ml		2879
		Dobutamine hydrochloride : 8 mg/ml Norepinephrine bitartrate : 0.32 mg/ml		1506
		Dobutamine hydrochloride : 4 mg/ml Oritavancin : 0.8 >>2 mg/ml		3152
		Dobutamine hydrochloride : 4 mg/ml Oxaliplatin : 0,5 mg/ml		1662
		Dobutamine hydrochloride : 1 mg/ml Pancuronium bromide : 0.05 mg/ml		402
		Dobutamine hydrochloride Pantoprazole sodium		2090
		Dobutamine hydrochloride : 1 >> 4 mg/ml Pantoprazole sodium : 0,16 >> 0,8 mg/ml		1902

		Dobutamine hydrochloride : < 4 mg/ml Pantoprazole sodium : < 0.05 mg/ml		1902
		Dobutamine hydrochloride : 12.5 mg/ml Paracetamol : 10 mg/ml		4742
		Dobutamine hydrochloride : 4 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Dobutamine hydrochloride : 1.2 mg/ml Pentoxifyllin : 5 mg/ml		4543
		Dobutamine hydrochloride : 2,4 & 7,2 mg/ml Pentoxifyllin : 5 mg/ml	 	4538
		Dobutamine hydrochloride : 2 mg/ml Pethidine hydrochloride : 100 mg/ml		1041
		Dobutamine hydrochloride : 1 mg/ml Pethidine hydrochloride : 10 mg/ml		62
		Dobutamine hydrochloride : 2 mg/ml Phentolamine mesylate : 0.04 mg/ml		1041
		Dobutamine hydrochloride : 2 mg/ml Phenylephrine hydrochloride : 0.04 mg/ml		1041
		Dobutamine hydrochloride : 2 mg/ml Phenytoin sodium : 50 mg/ml		1041
		Dobutamine hydrochloride : 1 mg/ml Phenytoin sodium : 1 mg/ml	 	1058
		Dobutamine hydrochloride : 4 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Dobutamine hydrochloride : 4.1 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Dobutamine hydrochloride Posaconazole		4380
		Dobutamine hydrochloride : 2 mg/ml Potassium chloride : 40 mEq/l		1041
		Dobutamine hydrochloride : 1 mg/ml Potassium chloride : 160 mEq/l	 	1058
		Dobutamine hydrochloride : 0.19 mg/ml Potassium phosphate		1221
		Dobutamine hydrochloride : 2 mg/ml Procainamide hydrochloride : 8 & 100 mg/ml		1041
		Dobutamine hydrochloride : 1 mg/ml Procainamide hydrochloride : 1 mg/ml	 	1058
		Dobutamine hydrochloride : 1 mg/ml Propofol		660
		Dobutamine hydrochloride : 4 mg/ml Propofol : 10 mg/ml		300
		Dobutamine hydrochloride : 2 mg/ml Propranolol hydrochloride : 1 mg/ml		1041
		Dobutamine hydrochloride : 4 mg/ml Ranitidine hydrochloride : 1 mg/ml		314
		Dobutamine hydrochloride : 0.25 & 1 mg/ml Ranitidine hydrochloride : 0.05 & 2 mg/ml	 	210
		Dobutamine hydrochloride : 1 mg/ml Ranitidine hydrochloride : 0,5 mg/ml		396
		Dobutamine hydrochloride : 0.25 & 1 mg/ml Ranitidine hydrochloride : 0.05 & 2 mg/ml	 	214

	Dobutamine hydrochloride : 4 mg/ml Remifentanyl hydrochloride : 25 & 250 µg/ml		59
	Dobutamine hydrochloride : 12.5 mg/ml Salbutamol sulfate : 1 mg/ml		3216
	Dobutamine hydrochloride Sodium bicarbonate		3606
	Dobutamine hydrochloride : 2 mg/ml Sodium bicarbonate : 84 mg/ml		1041
	Dobutamine hydrochloride : 1 mg/ml Sodium bicarbonate : 50 mg/ml		1058
	Dobutamine hydrochloride : 2 mg/ml Streptokinase : 30000 UI/ml		92
	Dobutamine hydrochloride : 12.5 mg/ml Sugammadex : 100 mg/ml		3372
	Dobutamine hydrochloride : 4,1 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
	Dobutamine hydrochloride : 1 mg/ml Tacrolimus : 1000 µg/ml		479
	Dobutamine hydrochloride : 4.1 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
	Dobutamine hydrochloride : 4 mg/ml Telavancin hydrochloride : 7.5 mg/ml		3254
	Dobutamine hydrochloride : 4 mg/ml Telavancin hydrochloride : 7.5 mg/ml	RL	3254
	Dobutamine hydrochloride : 1 mg/ml Temocilline : 83.33 mg/ml		2231
	Dobutamine hydrochloride : 1 mg/ml Theophylline : 4 mg/ml		317
	Dobutamine hydrochloride : 12.5 mg/ml Thiopental sodium : 25 mg/ml		3767
	Dobutamine hydrochloride : 4 mg/ml Thiopental sodium : 25 mg/ml		314
	Dobutamine hydrochloride : 4 mg/ml Thiotepa : 1 mg/ml		249
	Dobutamine hydrochloride Tigecycline		3332
	Dobutamine hydrochloride : 0,25 & 5 mg/ml Tirofiban : 50 µg/ml		1603
	Dobutamine hydrochloride Tirofiban		1512
	Dobutamine hydrochloride : 2 mg/ml Valproic acid : 10 mg/ml		3942
	Dobutamine hydrochloride : 1 mg/ml Vancomycin hydrochloride : 10 mg/ml		3385
	Dobutamine hydrochloride : 4.2 mg/ml Vasopressin : 2 & 4 UI/ml		1801
	Dobutamine hydrochloride : 4 mg/ml Vecuronium bromide : 1 mg/ml		314
	Dobutamine hydrochloride : 1 mg/ml Vecuronium bromide : 0.1 mg/ml		402
	Dobutamine hydrochloride : 0.25 mg/ml Verapamil hydrochloride : 0.16 mg/ml		1045

		Dobutamine hydrochloride : 0.5 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057
		Dobutamine hydrochloride : 2 mg/ml Verapamil hydrochloride : 2.5 mg/ml		1041
		Dobutamine hydrochloride : 1 mg/ml Warfarin sodium : 2 mg/ml		315
		Dobutamine hydrochloride : 5 mg/ml Zidovudine : 4 mg/ml		337
		Dobutamine hydrochloride : 1 mg/ml Zidovudine : 2 mg/ml		1878
		Dobutamine hydrochloride : 2 mg/ml		4655



Voie d'administration



Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
62	Revue	Pugh CB, Pabis DJ, Rodriguez C. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 123-125.
63	Revue	Marquardt Ed, Lam SSY. Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 811-812.
73	Revue	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
92	Revue	Lee CY, Mauro VF, Alexander KS. Visual and spectrophotometric determination of compatibility of alteplase and streptokinase with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 606-608.
93	Revue	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.

99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
176	Revue	Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
187	Revue	Olsen KM, Gurley BJ, Davis GA, Christensen R, Monaghan MS. Stability of flumazenil with selected drugs in 5% dextrose injection. Am J Hosp Pharm 1993 ; 50: 1907-1912.
196	Revue	Pramar Y, Das Gupta V, Neal Gardner S, Yau B. Stabilities of dobutamine, dopamine, nitroglycerin and sodium nitroprusside in disposable plastic syringes. J Clin Pharm Ther 1991 ; 16: 203-207.
197	Revue	Allwood MC. The stability of four catecholamines in 5% glucose infusions. J Clin Pharm Ther 1991 ; 16: 337-340.
198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
199	Revue	Hassan E, Leslie J, Martir-Herrero ML. Stability of labetalol hydrochloride with selected critical care drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 2143-2145.
206	Revue	Sautou-Miranda V, Gremeau I, Chamard I, Cassagnes J, Chopineau J. Stability of dopamine hydrochloride and of dobutamine hydrochloride in plastic syringes and administration sets. Am J Health-Syst Pharm 1996 ; 53: 186.
210	Revue	Stewart JT, Warren FW, King AD. Stability of ranitidine hydrochloride and seven medications. Am J Hosp Pharm 1994 ; 51: 1802-1807.
214	Revue	Galante LJ, Stewart JT, Warren FW, Edgar JW, Huff AJ. Stability of ranitidine hydrochloride with eight medications in intravenous admixtures. Am J Hosp Pharm 1990 ; 47: 1606-1610.
215	Revue	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
240	Revue	Lam XM, Ward CA, de C du M?e CPR. Stability and activity of alteplase with injectable drugs commonly used in cardiac therapy. Am J Health-Syst Pharm 1995 ; 52: 1904-1909.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
255	Revue	Ishisaka DY. Visual compatibility of fluconazole with drugs given by continuous infusion. Am J Hosp Pharm 1994 ; 51: 2290,2292.
266	Revue	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.

285	Revue	Elmore RL, Contois ME, Kelly J, Noe A, Poirier A. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther 1996 ; 18: 246-255.
288	Revue	Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: 957-958,961-962.
295	Revue	Yamashita SK, Walker SE, Choudhury T, Iazzetta J. Compatibility of selected critical care drugs during Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1048-1051.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
314	Revue	Chiu MF, Schwartz ML. Visual compatibility of injectable drugs used in the intensive care unit. Am J Health-Syst Pharm 1997 ; 54: 64-65.
315	Revue	Bahal SM, Lee TJ, McGinnes M, Dobler GL. Visual compatibility of warfarin sodium injection with selected medications and solutions. Am J Health-Syst Pharm 1997 ; 54: 2599-2600.
316	Revue	Veltri M, Lee CKK. Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs. Am J Health-Syst Pharm 1996 ; 53: 2611-2613.
317	Revue	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
336	Revue	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
337	Revue	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
396	Revue	Chilvers MR, Lysne JM. Visual compatibility of ranitidine hydrochloride with commonly used critical-care medications. Am J Hosp Pharm 1989 ; 46: 2057-2058.
398	Revue	Jay GT, Fanikos J, Souney PF. Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1556-1557.
402	Revue	Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821.
403	Revue	Outman WR, Monolakis J. Visual compatibility of haloperidol lactate with 0.9% sodium chloride injection or injectable critical-care drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 1539-1541.

467	Revue	Ishisaka DY, van Vleet J, Marquardt E. Visual compatibility of indomethacin sodium trihydrate with drugs given to neonates by continuous infusion. Am J Hosp Pharm 1991 ; 48: 2442-2443.
479	Revue	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
524	Revue	Farquhar Zanetti LA. Visual compatibility of diltiazem with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1992 ; 49: 1911.
628	Revue	Kirschenbaum HL, Aronoff W, Perentesis GP, Piltz GW, Goldberg RJ, Cutie AJ. Stability of dobutamine hydrochloride in selected large-volume parenterals. Am J Hosp Pharm 1982 ; 39: 1923-1925.
660	Revue	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
813	Revue	Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
939	Revue	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.
963	Revue	Schaaf LJ, Tremel LC, Wulf BG, Vernon KK. Compatibility of enalaprilat with dobutamine, dopamine, heparin, nitroglycerin, potassium chloride and nitroprusside. J Clin Pharm Ther 1990 ; 15: 371-376.
1036	Revue	Hasegawa GR, Eder JF. Visual compatibility of amiodarone hydrochloride injection with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 1379-1380.
1041	Revue	Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 949-951.
1045	Revue	Das Gupta V, Stewart KR. Stability of dobutamine hydrochloride and verapamil hydrochloride in 0.9% sodium chloride and 5 % dextrose injections. Am J Hosp Pharm 1984 ; 41: 686-689.
1057	Revue	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1058	Revue	Kirschenbaum HL, Aronoff W, Piltz GW, Perentesis GP, Cutie AJ. Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives. Am J Hosp Pharm 1983 ; 40: 1690-1691.
1067	Revue	Zeidler C, Dettmering D, Schrammel W, Spieteller M. Compatibility of various drugs used in intensive care medicine in polyethylene, PVC and glass infusion containers. EJHP 1999 ; 5: 106-110.
1072	Revue	Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.

1109	Revue	Horrow JC, Digregorio J, Barbieri EJ, Rupp E. Intravenous infusions of nitroprusside, dobutamine, and nitroglycerin are compatible. Crit Care Med 1990 ; 18: 858-861.
1221	Revue	Dahlin PA, Paredes SM. Visual compatibility of dobutamine with seven parenteral drug products. Am J Hosp Pharm 1980 ; 37: 460,464.
1232	Revue	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1315	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1352	Revue	Hasegawa GR, Eder JF. Dobutamine-heparin mixture inadvisable. Am J Hosp Pharm 1984 ; 41: 2588-2589.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1490	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1496	Revue	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1506	Revue	Lopez-Cabezas C, Guerrero L, Molas G, Anglada H, Soy D. Physicochemical compatibility of high concentration drugs usually Y-site administered in intensive care units. EJHP 2015 ;22:107-112.
1508	Revue	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1512	Laboratoire	Tirofiban (Aggrastat®) - Summary of Product Characteristics Beacon Pharmaceuticals Ltd 2015
1603	Revue	Bergquist PA, Manas D, Hunke WA, Reed RA. Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs. Am J Health-Syst Pharm 2001 ; 58: 1218-1223.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Revue	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1703	Revue	Schuster F, Bernard R. Kompatibilität von enalaprilat i.v. mit ausgewählten Arzneimitteln. Krankenhauspharmazie 1995 ; 16: 101-103.

1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1753	Revue	Webster AA, English BA, McGuire JM, Riggs RM, Lander V, Buckle T. Stability of dobutamine hydrochloride 4 mg/ml in 5% dextrose injection at 5 and 23°C. Int J Pharm Compound 1999 ; 3: 412-414.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1801	Revue	Feddema S, Rusho WJ, Tyler LS, Barker B. Physical compatibility of vasopressin with medications commonly used in cardiac arrest. Am J Health-Syst Pharm 2003 ; 60: 1271-1272.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1878	Revue	Musami P, Stewart JT, Will Taylor E. Stability of zidovudine and dobutamine hydrochloride injections in 0.9% sodium chloride and 5% dextrose injections stored at ambient temperature (23±2°C) and 4°C in 50 ml polyvinyl chloride bags up to 24 hours. Int J Pharm Compound 2004 ; 8, 1: 73-76.
1902	Revue	Walker SE, Wyllie A, Law S. Physical compatibility of pantoprazole with selected medications during simulated Y-site administration. Can J Hosp Pharm 2004 ; 57, 2: 90-96.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1944	Revue	Hartman CA, Faria CE, Mago K. Visual compatibility of bivalirudin with selected drugs. Am J Health-Syst Pharm 2004 ; 61: 1774.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1964	Revue	Hartman CA, Baroletti SA, Churchill WW et al. Visual compatibility of argatroban with selected drugs. Am J Health-Syst Pharm 2002 ; 59: 1784-1785.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2018	Revue	Veggeland T. Visual compatibility of clonidine with selected drugs. Am J Health-Syst Pharm 2005 ; 62: 1968-1969.
2087	Revue	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.

2108	Revue	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2109	Revue	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2141	Revue	Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003 ; 51: 651-658.
2231	Revue	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2233	Revue	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2371	Revue	Gora ML, Seth S, Visconti JA, Shields B, Bay W. Stability of dobutamine hydrochloride in peritoneal dialysis solutions Am J Hosp Pharm 1991 ; 48: 1234 - 1237.
2879	Poster	Imesch G., Humbert-Delaloye V., Berger M., Pannatier A. Compatibilité entre amiodarone, catecholamines et/ou nitroprussiate de sodium, administré en continu par voie veineuse aux soins intensifs adultes. GSASA Congress - Lucerne - Switzerland 2008
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3152	Revue	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3177	Poster	Humbert-Delaloye V, Berger M, Pannatier A. Compatibilités physico-chimique entre catécholamines, amiodarone, et/ou nitroprussiate de sodium intraveineux. 16èmes JFSPH, Sion, 18-19 novembre 2010 2010
3201	Revue	Dice JE. Physical compatibility of alprostadil with commonly used IV solutions and medications in the neonatal intensive care unit. J Pediatr Pharmacol Ther 2006 ; 11:233?6.
3210	Revue	Jasti Bhaskara R, Saraf Poonam. Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations. Int J Pharm Compound 2011 ; 15, 3: 259-261.






























3216	Revue	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Revue	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3293	Revue	Patel N, Taki M, Tunstell P, Forsey P, Forbes B. Stability of dobutamine 500 mg in 50 ml syringes prepared using a Central Intravenous Additive Service EJHP 2012 ; 19: 52-56.
3332	Laboratoire	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3372	Revue	Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anesthesiol 2013 ; 63, 1: 163-166.
3381	Revue	Humbert-Delaloye V, Berger-Gryllaki M, Voirol P, Gattlen L, Pannatier A. In vitro compatibility of various cardioactive drugs during simulated Y-site administration. EJHP 2013 ; 20:110-116.
3385	Revue	Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182.
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3539	Laboratoire	Bivalirudin (Angiox®) - Summary of Product Characteristics. The Medecines Company 2013
3540	Laboratoire	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3595	Laboratoire	Aciclovir - Summary of Product Characteristics Hospira 2009
3606	Laboratoire	Dobutamine - Summary of Product Characteristics Wokhardt 2013
3644	Laboratoire	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3715	Revue	Mauro V.F, Howard M.S, Boddu S.H.S, Churchwell M.D. Compatibility of conivaptan injection with select cardiovascular medications. Am J Health-Syst Pharm 2014 ; 71:1534-1535
3766	Revue	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3823	Revue	Juan E.P, Palau M.M, Cerdá S.A, Rubert M.A, Nicolau B.R. Compatibilité physique de médicaments administrés dans l'unité de soins intensifs Pharmactuel 2015 ; 48, 3 : 146-152.















3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3932	Laboratoire	Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit Serb Laboratoire 2015
3934	Laboratoire	Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit GlaxoSmithKline Laboratoire 2016
3942	Revue	Frank M.I, Boddu S.H.S, Mauro V.F, Churchwell M.D. Physical compatibility of valproate sodium injection with dobutamine and dopamine. Am J Health-Syst Pharm 2017 ; 74, 5: 280-281.
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4108	Revue	Cruz K, Churchwell M, Mauro V, Boddu. Physical compatibility of levetiracetam injection with heparin, dobutamine, and dopamine. Am J Health-Syst Pharm 2018 ;75;8:510-512
4119	Poster	Marcoz N, Ing H, Sautter AM, Saadi JF, Roulin JF, Bonnabry P. Stabilité et compatibilité de solutions injectables d'amiodarone (Cordarone®) Hôpitaux Universitaire de Genève 2004
4141	Revue	Al Madfai F, Valah B, Zaidi S.T.R, Wanandy T, Ming M.C, Peterson G.M, Patel R.P. Stability of dobutamine in continuous ambulatory delivery devices. J Clin Pharm Ther 2018 : 530-535.
4145	Revue	Asempta T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	Revue	Lessard J-J, Caron E, Schérier H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4380	Laboratoire	Posaconazole (Noxafil®) - Summary of Product Characteristics Merck Sharp & Dohme Limited 2019
4419	Revue	Holt R.J, Siegert S.W.K, Krishna A. Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection. J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.
4433	Revue	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4434	Revue	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.

4491	Revue	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pilar P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2020
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4538	Revue	Campbell A, Petrovski M, Senarathna G, Mukadam ,Strunk T, Batty K. Compatibility of pentoxifylline and parenteral medications. Archives of Disease in Childhood 2020 ; 105: 395-397.
4543	Revue	Senarathna G, Strunk T, Petrovski M, Batty K. Physical compatibility of pentoxifylline and intravenous medications. Archives of Disease in Childhood 2018 ;104:292–295.
4584	Revue	Gilliot S, Henry H, Carta N, Genay S, Barthélémy C, Décaudin B, Odou P. Long-term stability of 10 mg/mL dobutamine injectable solutions in 5% dextrose and normal saline solution stored in polypropylene syringes and cyclic-oleofin- copolymer vials. EJHP 2023 ; 30, 3: 153-159.
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4650	Laboratoire	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4651	Revue	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pascual P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2021 ;180,1169–1176.
4655	Revue	Holyk A, Lindner A, Lindner S, Shippert B Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration. Am J Health-Syst Pharm 2022 ;79,1:27-33
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:



Dictionnaire

 Cardiotonique	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Verre
 NaCl 0,9% ou glucose 5%	 A l'abri de la lumière
 Jour	 NaCl 0,45% Glucose 5%
 Lumière	 Heure
 Polyvinyl chlorure	 Non précisée
 Glucose 5%	RL Ringer lactate
 Dianéal® PD1 1.5% glucose (Baxter)	 Polyéthylène
 Seringue polypropylène	 Chlorure de sodium 0,9%
 Avec ou sans lumière	 AT-Closed vial®
 Non précisé	 Stabilité en mélange
 Solvant	 Molécule
 Polypropylène	 Facteur influençant la stabilité
 Provoque	 Dégradation
 Augmentation stabilité	 NaHCO ₃
 Compatibilités	 Changement de couleur après 1 heure
 Incompatible	 Incompatibilité non précisée
 Compatible	 Précipitation immédiate
 Eau pour préparation injectable	 Précipitation en 12 heures
 Turbidité en 4 heures	 Turbidité immédiate
 Changement de couleur en 24 heures	 Changement de couleur
 Aucun	 Turbidité à 24 heures
 Précipitation en 24 heures	 Nutrition parentérale (mélange binaire)
 NaCl 0,9% + bactériostatique	 Précipitation en 15 minutes
 Changement de couleur à 4 heures	 Précipitation en 6 heures

 Turbidité en 1 heure	 Précipitation en 4 heures
 Changement de couleur à 6 heures	 Solvant spécifique
 Nutrition parentérale (mélange ternaire)	 Précipitation en 8 heures
 Instabilité chimique	 Précipitation en 1 heure
 Instabilité de l'émulsion à 12 heures	 Normosol®
 Voie d'administration	 Perfusion continue
 Bibliographie	 Dictionnaire